Sat Kartar (SATKARTAR)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹205, Sat Kartar wears the mask of a small pharma player, but the underlying numbers deserve a Graham-style look. Market cap ₹277 Cr, P/E 20.08. ROCE 39.66% is exceptional; this suggests the business earns strong returns on capital employed. The 103.93% jump in profit is striking, but I never buy for one year's earnings alone. Sales grew only 16.57%, so much of the profit leap must be margin expansion or a low base. With a PEG of 0.33, the market is pricing in sustained fast growth; if growth falters, the arithmetic turns unfavourable. Latest quarter sales ₹88 Cr and net profit ₹8 Cr mean a modest 9% net margin, so it is not a high-margin franchise yet. Piotroski F-score of 7/9 is encouraging and points to a fundamentally sound balance sheet, though the absence of book value, ROE and debt-equity data prevents me from concluding financial strength with confidence. Promoter holding at 63.62% is a positive; owners have skin in the game. Dividend yield of 0.40% is merely a token, so returns must come from growth, not dividends. The stock trades near its 52-week high of ₹219.80, with a low of ₹116.25, leaving little margin of safety. My discipline: rate the business, not the momentum. A 16.57% sales grower with 100% profit growth into a market cap of ₹277 Cr can be a fast grower, but I would demand several more quarters of reliable cash profit and cleaner disclosures before deploying capital. The F-score and ROCE are good starting red flags in the right direction, but capital preservation demands proof.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer